ETCTN A Phase II Study of the PARP Inhibitor Olaparib in Combination with the DNA Damaging Agent Temozolomide for the Treatment of Advanced Uterine Leiomyosarcoma Adult CIRB - Early Phase Emphasis Active Available to Open